Document



 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 21, 2019
 
 
GLOBUS MEDICAL, INC.
(Exact name of registrant as specified in charter)
 
 
 
DELAWARE
 
001-35621
 
04-3744954
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403
(Address of principal executive offices) (Zip Code)
(610) 930-1800
(Registrant’s telephone number, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o






Item 2.02. Results of Operations and Financial Condition.
On February 21, 2019, we issued a press release reporting, among other things, our sales and operating results for the three and twelve month periods ended ended December 31, 2018. A copy of the press release is furnished as Exhibit 99.1 to this report.
In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibits attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.
Description
 
 
99.1
 
 






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
 
GLOBUS MEDICAL, INC.
 
 
(Registrant)
 
 
 
Dated:
February 21, 2019
/s/ DANIEL T. SCAVILLA
 
 
 
 
 
Daniel T. Scavilla
 
 
Executive Vice President,
 
 
Chief Financial Officer
 
 
Chief Commercial Officer



Exhibit


Exhibit 99.1


Globus Medical Reports Full Year and Fourth Quarter 2018 Results

AUDUBON, PA, February 21, 2019: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2018.
Fourth Quarter:
Worldwide sales increased 11.3% as reported to $195.9 million
Fourth quarter net income was $36.8 million, or 18.8% of sales.
Diluted earnings per share (EPS) were $0.36
Non-GAAP diluted EPS were $0.43
Non-GAAP adjusted EBITDA was 34.1% of sales

Full Year 2018:
Worldwide sales increased 12.1% as reported to $713.0 million
Net income for the year was $156.5 million, or 21.9% of sales
Diluted EPS were $1.54
Non-GAAP diluted EPS were $1.67
Non-GAAP adjusted EBITDA was 34.5% of sales

“Our fourth quarter and full year results are indicative of strong momentum in several key strategic areas,” said Dave Demski, CEO. “The fourth quarter marked the fifth consecutive quarter of double digit organic revenue growth, which is particularly outstanding considering the strong comparable quarter last year. Emerging Technologies delivered $14.7 million, or 34.1% growth, a significant accomplishment given the pent up demand implicit in the fourth quarter of 2017 when we launched our robotic system. The U.S. spinal implant business grew by over 9.4% year-over-year, continuing the acceleration we saw in the third quarter, driven by robotic implant pull through and strong recruiting.”

Full year 2018 sales were $713.0 million, a 12.1% increase over 2017, and non-GAAP EPS was $1.67. Worldwide sales for the fourth quarter were $195.9 million, an increase of 11.3% over the fourth quarter of 2017.  Revenue from Emerging Technologies was primarily due to continued demand for the ExcelsiusGPS® robotics and navigation system.

Fourth quarter sales in the U.S., including robotics, increased by 10.7% compared to the fourth quarter of 2017. International sales increased by 14.7% over the fourth quarter of 2017 on an as-reported basis and 16.8% on a constant currency basis.

Fourth quarter GAAP net income was $36.8 million, an increase of 50.8% over the same period last year. Diluted EPS for the fourth quarter was $0.36, as compared to $0.25 for the fourth quarter 2017. Non-GAAP diluted EPS for the fourth quarter was $0.43, compared to $0.38 in the fourth quarter of 2018, an increase of 15.1%.

The company generated net cash provided by operating activities of $181.6 million and non-GAAP free cash flow of $121.9 million in 2018. The Company ended the year with cash, cash equivalents and marketable securities of $602.8 million. The company remains debt free.

2019 Annual Guidance
The company today confirmed full year 2019 guidance with sales of $770 million and non-GAAP diluted earnings per share of $1.72.





Conference Call Information
Globus Medical will hold a teleconference to discuss its 2018 fourth quarter and full year results with the investment community at 4:30 p.m. Eastern Time today. Globus invites all interested parties to join the call by dialing:
 
1-855-533-7141     United States Participants
1-720-545-0060     International Participants
There is no pass code for the teleconference.

For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at investors.globusmedical.com.

The call will be archived until Thursday, February 21, 2019. The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 1012-6378.
About Globus Medical, Inc.
Based in Audubon, Pennsylvania, Globus Medical, Inc. was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.
Non-GAAP Financial Measures
To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures.  For example, non-GAAP adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation, provisions for litigation, and acquisition related costs/licensing, and net gain from the sale of assets, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense.  Our management also uses non-GAAP adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections.  Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized.  Acquisition related costs/licensing represents the change in fair value of business acquisition related contingent consideration; costs related to integrating recently acquired businesses including but not limited to costs to exit or convert contractual obligations, severance, and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees, as well as one-time licensing fees. Net gain from sale of assets represents the gain on sale of assets and the offsetting impact of costs incurred through the sale.





In addition, for the period ended December 31, 2018 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted earnings per share, which represents net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, acquisition related costs/licensing, net gain from the sale of assets and the tax effects of such adjustments.  We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of litigation, amortization of intangibles, acquisition related costs/licensing, net gain from the sale of assets and the tax effects of such adjustments, which we believe are not reflective of underlying business trends.  Additionally, for the periods ended December 31, 2018 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment.  We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions.  Furthermore, the non-GAAP measure of constant currency sales growth is calculated by translating current year sales at the same average exchange rates in effect during the applicable prior year period.  We believe constant currency sales growth provides insight to the comparative increase or decrease in period sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.
Non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency sales growth are not calculated in conformity with U.S. GAAP.  Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP.  These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results.  Our definitions of non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency sales growth may differ from that of other companies and therefore may not be comparable.  Additionally, we have recast prior periods for non-GAAP net income and non-GAAP diluted earnings per share.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms.  These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends.  Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted.  These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to successfully integrate the international operations acquired from Alphatec, both in general and on our anticipated timeline, our ability to transition Alphatec’s international customers to Globus products, our ability to realize the expected benefits to our results from the Alphatec acquisition, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks.  For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission.  These documents are available at www.sec.gov.  Moreover, we operate in an evolving environment.  New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor,





or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.  Forward-looking statements contained in this press release speak only as of the date of this press release.  We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.





GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)

 
Three Months Ended
 
Year Ended
(In thousands, except per share amounts)
December 31,
2018
 
December 31,
2017
 
December 31,
2018
 
December 31,
2017
Sales
$
195,938

 
$
176,034

 
$
712,969

 
$
635,977

Cost of goods sold
45,954

 
40,856

 
159,410

 
150,453

Gross profit
149,984

 
135,178

 
553,559

 
485,524

 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
Research and development
13,758

 
11,413

 
55,496

 
43,679

Selling, general and administrative
83,642

 
72,958

 
311,591

 
267,817

Provision for litigation
5,878

 
(112
)
 
5,878

 
2,668

Amortization of intangibles
3,063

 
2,238

 
9,588

 
7,909

Acquisition related costs
392

 
321

 
1,681

 
1,611

Total operating expenses
106,733

 
86,818

 
384,234

 
323,684

 
 
 
 
 
 
 
 
Operating income
43,251

 
48,360

 
169,325

 
161,840

Other income/(expense), net
4,376

 
2,240

 
19,280

 
8,088

Income before income taxes
47,627

 
50,600

 
188,605

 
169,928

Income tax provision
10,876

 
26,224

 
32,131

 
62,580

 
 
 
 
 
 
 
 
Net income
$
36,751

 
$
24,376

 
$
156,474

 
$
107,348

 
 
 
 
 
 
 
 
Earnings per share:
 
 
 
 
 
 
 
Basic
$
0.37

 
$
0.25

 
$
1.60

 
$
1.12

Diluted
$
0.36

 
$
0.25

 
$
1.54

 
$
1.10

Weighted average shares outstanding:
 
 
 
 
 
 
 
Basic
98,516

 
96,489

 
97,884

 
96,243

Diluted
101,627

 
98,726

 
101,316

 
97,887






GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)
December 31,
2018
 
December 31,
2017
 
 
 
 
ASSETS
(unaudited)
 
 
Current assets:
 
 
 
Cash, cash equivalents, and restricted cash
$
139,747

 
$
118,817

Short-term marketable securities
199,937

 
254,890

Accounts receivable, net of allowances of $4,226 and $3,963, respectively
137,067

 
116,676

Inventories
131,254

 
108,409

Prepaid expenses and other current assets
15,387

 
11,166

Current portion of note receivable

 
1,667

Income taxes receivable
7,289

 
8,717

Total current assets
630,681

 
620,342

Property and equipment, net of accumulated depreciation of $216,809 and $191,760, respectively
171,873

 
143,167

Long-term marketable securities
263,117

 
56,133

Note receivable

 
28,333

Intangible assets, net
87,323

 
78,659

Goodwill
123,734

 
123,890

Other assets
10,364

 
7,947

Deferred income taxes
13,578

 
20,031

Total assets
$
1,300,670

 
$
1,078,502

 
 
 
 
LIABILITIES AND EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
25,895

 
$
25,039

Accrued expenses
59,878

 
52,594

Income taxes payable
917

 
3,274

Business acquisition liabilities
6,830

 
11,411

Deferred revenue
2,598

 
755

Total current liabilities
96,118

 
93,073

Business acquisition liabilities, net of current portion
3,288

 
4,508

Deferred income taxes
8,114

 
10,669

Other liabilities
7,634

 
2,474

Total liabilities
115,154

 
110,724

Commitments and contingencies
 
 
 
Equity:
 
 
 
Common stock; $0.001 par value. Authorized 785,000 shares; issued and outstanding 98,573 and 96,658 shares at December 31, 2018 and December 31, 2017, respectively
98

 
97

Additional paid-in capital
299,869

 
238,341

Accumulated other comprehensive loss
(7,172
)
 
(6,907
)
Retained earnings
892,721

 
736,247

Total equity
1,185,516

 
967,778

Total liabilities and equity
$
1,300,670

 
$
1,078,502






GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
 
Year Ended
(In thousands)
December 31,
2018
 
December 31,
2017
Cash flows from operating activities:
 
 
 
Net income
$
156,474

 
$
107,348

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
41,630

 
42,067

Amortization of premium on marketable securities
1,677

 
2,671

Write-down for excess and obsolete inventories
10,475

 
11,519

Stock-based compensation expense
21,899

 
14,686

Allowance for doubtful accounts
957

 
1,718

Change in fair value of business acquisition liabilities
985

 
1,240

Impairment of intangible assets


 
516

Change in deferred income taxes
971

 
8,292

(Gain)/loss on disposal of assets, net
(3,557
)
 

(Increase)/decrease in:
 
 
 
Accounts receivable
(21,789
)
 
(24,955
)
Inventories
(31,382
)
 
(5,277
)
Prepaid expenses and other assets
(7,496
)
 
(4,774
)
Increase/(decrease) in:
 
 
 
Accounts payable
(3,008
)
 
9,843

Accrued expenses and other liabilities
14,728

 
(2,064
)
Income taxes payable/receivable
(921
)
 
(3,772
)
Net cash provided by operating activities
181,643

 
159,058

 
 
 
 
Cash flows from investing activities:
 
 
 
Purchases of marketable securities
(537,942
)
 
(392,895
)
Maturities of marketable securities
278,049

 
240,353

Sales of marketable securities
106,388

 
122,512

Purchases of property and equipment
(59,697
)
 
(51,303
)
Collections/(issuance) of note receivable
30,000

 

Proceeds from sale of assets
5,000

 

Acquisition of businesses, net of cash acquired, and purchases of intangible and other assets
(14,825
)
 
(29,944
)
Net cash used in investing activities
(193,027
)
 
(111,277
)
 
 
 
 
Cash flows from financing activities:
 
 
 
Payment of business acquisition liabilities
(6,739
)
 
(10,109
)
Proceeds from exercise of stock options
39,309

 
11,735

Net cash provided by financing activities
32,570

 
1,626

 
 
 
 
Effect of foreign exchange rate on cash
(256
)
 
1,979

 
 
 
 
Net increase in cash, cash equivalents, and restricted cash
20,930

 
51,386

Cash, cash equivalents, and restricted cash, beginning of period
118,817

 
67,431

Cash, cash equivalents, and restricted cash, end of period
$
139,747

 
$
118,817

 
 
 
 
Supplemental disclosures of cash flow information:
 
 
 
Interest paid
6

 
3

Income taxes paid
$
30,552

 
$
59,111







Supplemental Financial Information

Sales by Geographic Area:
(Unaudited)
Three Months Ended
 
Year Ended
(In thousands)
December 31,
2018
 
December 31,
2017
 
December 31,
2018
 
December 31,
2017
United States
$
163,788

 
$
148,012

 
$
593,878

 
$
529,882

International
32,150

 
28,022

 
119,091

 
106,095

Total sales
$
195,938

 
$
176,034

 
$
712,969

 
$
635,977

 
Sales by Revenue Stream:
(Unaudited)
Three Months Ended
 
Year Ended
(In thousands)
December 31,
2018
 
December 31,
2017
 
December 31,
2018
 
December 31,
2017
Musculoskeletal Solutions products
$
181,638

 
$
165,114

 
$
666,040

 
$
625,057

Enabling Technologies products
14,300

 
10,920

 
46,929

 
10,920

Total sales
$
195,938

 
$
176,034

 
$
712,969

 
$
635,977

(Unaudited)
Three Months Ended
 
Year Ended
(In thousands)
December 31,
2018
 
December 31,
2017
 
December 31,
2018
 
December 31,
2017
Spine products
$
181,254

 
$
165,087

 
$
665,403

 
$
625,027

Emerging Technology Products
14,684

 
10,947

 
47,566

 
10,950

Total sales
$
195,938

 
$
176,034

 
$
712,969

 
$
635,977

Liquidity and Capital Resources:
(Unaudited)
December 31,
2018
 
December 31,
2017
(In thousands)
 
 
 
Cash, cash equivalents, and restricted cash
$
139,747

 
$
118,817

Short-term marketable securities
199,937

 
254,890

Long-term marketable securities
263,117

 
56,133

Total cash, cash equivalents, restricted cash, and marketable securities

$
602,801

 
$
429,840









The following tables reconcile GAAP to Non-GAAP financial measures.
Non-GAAP Adjusted EBITDA Reconciliation Table:
(Unaudited)
Three Months Ended
 
Year Ended
(In thousands, except percentages)
December 31,
2018
 
December 31,
2017
 
December 31,
2018
 
December 31,
2017
Net income
$
36,751

 
$
24,376

 
$
156,474

 
$
107,348

Interest income, net
(4,164
)
 
(1,862
)
 
(13,278
)
 
(6,608
)
Provision for income taxes
10,876

 
26,224

 
32,131

 
62,580

Depreciation and amortization
11,936

 
8,294

 
41,630

 
42,067

EBITDA
55,399

 
57,032

 
216,957

 
205,387

Stock-based compensation expense
4,821

 
4,027

 
21,899

 
14,686

Provision for litigation
5,878

 
(112
)
 
5,878

 
2,668

Acquisition related costs/licensing
641

 
553

 
4,488

 
3,391

Net gain from sale of assets

 

 
(3,593
)
 

Adjusted EBITDA
$
66,739

 
$
61,500

 
$
245,629

 
$
226,132

 
 
 
 
 
 
 
 
Net income as a percentage of sales
18.8
%
 
13.8
%
 
21.9
%
 
16.9
%
Adjusted EBITDA as a percentage of sales
34.1
%
 
34.9
%
 
34.5
%
 
35.6
%

Non-GAAP Net Income Reconciliation Table:
(Unaudited)
Three Months Ended
 
Year Ended
(In thousands)
December 31,
2018
 
December 31,
2017
 
December 31,
2018
 
December 31,
2017
Net income
$
36,751

 
$
24,376

 
$
156,474

 
$
107,348

Provision for litigation
5,878

 
(112
)
 
5,878

 
2,668

Amortization of intangibles
3,063

 
2,238

 
9,588

 
7,909

Acquisition related costs/licensing
641

 
553

 
4,488

 
3,391

Net gain from sale of assets

 

 
(3,593
)
 

Tax reform impact


 
11,014

 

 
11,014

Tax effect of adjusting items
(2,189
)
 
(796
)
 
(3,437
)
 
(4,239
)
Non-GAAP net income
$
44,144

 
$
37,273

 
$
169,398

 
$
128,091






Non-GAAP Diluted Earnings Per Share Reconciliation Table:
(Unaudited)
Three Months Ended
 
Year Ended
(Per share amounts)
December 31,
2018
 
December 31,
2017
 
December 31,
2018
 
December 31,
2017
Diluted earnings per share, as reported
$
0.36

 
$
0.25

 
$
1.54

 
$
1.10

Provision for litigation
0.06

 

 
0.06

 
0.03

Amortization of intangibles
0.03

 
0.02

 
0.09

 
0.08

Acquisition related costs/licensing
0.01

 
0.01

 
0.05

 
0.03

Net gain from sale of assets

 

 
(0.04
)
 

Tax reform impact


 
0.11

 

 
0.11

Tax effect of adjusting items
(0.02
)
 
(0.01
)
 
(0.03
)
 
(0.04
)
Non-GAAP diluted earnings per share
$
0.43

 
$
0.38

 
$
1.67

 
$
1.31

* amounts might not add due to rounding
 
 
 
 
 
 
 
Non-GAAP Free Cash Flow Reconciliation Table:
(Unaudited)
Three Months Ended
 
Year Ended
(In thousands)
December 31,
2018
 
December 31,
2017
 
December 31,
2018
 
December 31,
2017
Net cash provided by operating activities
$
44,291

 
$
44,837

 
$
181,643

 
$
159,058

Purchases of property and equipment
(17,159
)
 
(13,425
)
 
(59,697
)
 
(51,303
)
Non-GAAP free cash flow
$
27,132

 
$
31,412

 
$
121,946

 
$
107,755

Non-GAAP Sales on a Constant Currency Basis Comparative Table:
(Unaudited)
Three Months Ended
 
Reported Growth
 
Currency Impact on 2018 Sales

 
Constant Currency Sales Growth

(In thousands, except percentages)
December 31,
2018
 
December 31,
2017
 
 
 
United States
$
163,788

 
$
148,012

 
10.7
%
 

 
10.7
%
International
32,150

 
28,022

 
14.7
%
 
$
570

 
16.8
%
Total sales
$
195,938

 
$
176,034

 
11.3
%
 
$
570

 
11.6
%
(Unaudited)
Year Ended
 
Reported Growth
 
Currency Impact on 2018 Sales

 
Constant Currency Sales Growth

(In thousands, except percentages)
December 31,
2018
 
December 31,
2017
 
 
 
United States
$
593,878

 
$
529,882

 
12.1
%
 

 
12.1
%
International
119,091

 
106,095

 
12.2
%
 
$
(1,494
)
 
10.8
%
Total sales
$
712,969

 
$
635,977

 
12.1
%
 
$
(1,494
)
 
11.9
%

Contact:
Brian Kearns
Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email:     investors@globusmedical.com
www.globusmedical.com